Gordon Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gordon Li has a total of 318 co-authors. Here are the top co-authors by number of shared publications:
- Michael Lim
Department of Neurosurgery, Stanford University, Palo Alto, CA, USA
29 shared publications - Ryan Takeo Nitta
Department of Neurosurgery, Stanford University School of Medicine, Stanford, California
23 shared publications - Ayush Pant
Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland
19 shared publications - Caren Yu-Ju Wu
Department of Neurosurgery, Keelung Chang Gung Medical Foundation, Keelung, Taiwan
19 shared publications - Christopher M. Jackson
Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD
19 shared publications - Crystal L. Mackall
Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA
19 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from The CCR6–CCL20 Axis Promotes Regulatory T-cell Glycolysis and Immunosuppression in Tumors
Figure S2: CCR6 expression is enhanced in tumor-infiltrating Tregs co-expressing checkpoints and Ccr6 ablation reduces immunosuppressive phenotype.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from The CCR6–CCL20 Axis Promotes Regulatory T-cell Glycolysis and Immunosuppression in Tumors
Figure S2: CCR6 expression is enhanced in tumor-infiltrating Tregs co-expressing checkpoints and Ccr6 ablation reduces immunosuppressive phenotype.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from The CCR6–CCL20 Axis Promotes Regulatory T-cell Glycolysis and Immunosuppression in Tumors
Figure S3: Ccr6-/- Tregs are transcriptionally and metabolically distinct from WT Tregs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from The CCR6–CCL20 Axis Promotes Regulatory T-cell Glycolysis and Immunosuppression in Tumors
Figure S3: Ccr6-/- Tregs are transcriptionally and metabolically distinct from WT Tregs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from The CCR6–CCL20 Axis Promotes Regulatory T-cell Glycolysis and Immunosuppression in Tumors
Figure S1: CCR6 and CCL20 expression is increased in multiple tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from The CCR6–CCL20 Axis Promotes Regulatory T-cell Glycolysis and Immunosuppression in Tumors
Figure S1: CCR6 and CCL20 expression is increased in multiple tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from The CCR6–CCL20 Axis Promotes Regulatory T-cell Glycolysis and Immunosuppression in Tumors
Figure S5: Ccr6 ablation reduces Treg immunosuppression of CD8 T cells in the context of tumor growth.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from The CCR6–CCL20 Axis Promotes Regulatory T-cell Glycolysis and Immunosuppression in Tumors
Figure S5: Ccr6 ablation reduces Treg immunosuppression of CD8 T cells in the context of tumor growth.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from The CCR6–CCL20 Axis Promotes Regulatory T-cell Glycolysis and Immunosuppression in Tumors
Figure S4: Ccr6-/- Tregs have reduced glycolysis compared to WT Tregs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from The CCR6–CCL20 Axis Promotes Regulatory T-cell Glycolysis and Immunosuppression in Tumors
Figure S4: Ccr6-/- Tregs have reduced glycolysis compared to WT Tregs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from The CCR6–CCL20 Axis Promotes Regulatory T-cell Glycolysis and Immunosuppression in Tumors
Figure S6: Ccr6 ablation delays tumor growth across multiple tumor models and CCR6CCL20 expression correlates with overall survival in cancer patients.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from The CCR6–CCL20 Axis Promotes Regulatory T-cell Glycolysis and Immunosuppression in Tumors
Figure S6: Ccr6 ablation delays tumor growth across multiple tumor models and CCR6CCL20 expression correlates with overall survival in cancer patients.
- 14 January 2026
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 176 (2) , 168
Surgical resection versus stereotactic radiosurgery for succinate dehydrogenase-related hereditary head and neck paragangliomas
- 14 January 2026
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 176 (2) , 168
Surgical resection versus stereotactic radiosurgery for succinate dehydrogenase-related hereditary head and neck paragangliomas
- Open Access
- 24 November 2025
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 99 (1) , 149-159
Combination of Neuronavigation-Guided Focused Ultrasound and Bevacizumab for Patients With Recurrent Glioblastoma: A Pilot Study
BACKGROUND AND OBJECTIVES: Combining focused ultrasound (FUS)–induced blood-brain barrier opening with bevacizumab (BEV) has demonstrated survival benefits in preclinical models. This study aimed to evaluate the safety and feasibility of repeated FUS-BEV treatments in patients with recurrent glioblastoma and to explore imaging and serum biomarkers in relation to disease status. METHODS: This was a prospective, single-arm, open-label pilot trial. The primary end point was 6-month progression-free survival (PFS). Disease progression was assessed according to the Response Assessment in Neuro-Oncology criteria by independent radiological review. Radiological response was evaluated using fluid-attenuated inversion-recovery sequences to compare FUS-exposed vs nonexposed regions. Plasma cell–free DNA (cfDNA) concentrations were measured before and after FUS treatment. RESULTS: Between July 2020 and August 2023, 6 patients received a median of 14.5 sessions of biweekly FUS-BEV (10 mg/kg). The median PFS was 11 months, with a 6-month PFS rate of 66.7%. The only FUS-related adverse event was transient scalp heating (grade 1; 1.9%). A fluid-attenuated inversion recovery normalization effect emerged within 1 month after treatment. Plasma cfDNA increased significantly post-FUS, with total cfDNA rising 2.03 ± 0.76-fold, EGFR cfDNA 1.77 ± 0.76-fold, and HMBS cfDNA 1.68 ± 0.66-fold. CONCLUSION: Repeated FUS-BEV treatment is safe and feasible in patients with recurrent glioblastoma. Randomized controlled trials are warranted to confirm its therapeutic efficacy and validate imaging and liquid biopsy biomarkers.
- 24 November 2025
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 99 (1) , 149-159
Open AccessCombination of Neuronavigation-Guided Focused Ultrasound and Bevacizumab for Patients With Recurrent Glioblastoma: A Pilot Study
BACKGROUND AND OBJECTIVES: Combining focused ultrasound (FUS)–induced blood-brain barrier opening with bevacizumab (BEV) has demonstrated survival benefits in preclinical models. This study aimed to evaluate the safety and feasibility of repeated FUS-BEV treatments in patients with recurrent glioblastoma and to explore imaging and serum biomarkers in relation to disease status. METHODS: This was a prospective, single-arm, open-label pilot trial. The primary end point was 6-month progression-free survival (PFS). Disease progression was assessed according to the Response Assessment in Neuro-Oncology criteria by independent radiological review. Radiological response was evaluated using fluid-attenuated inversion-recovery sequences to compare FUS-exposed vs nonexposed regions. Plasma cell–free DNA (cfDNA) concentrations were measured before and after FUS treatment. RESULTS: Between July 2020 and August 2023, 6 patients received a median of 14.5 sessions of biweekly FUS-BEV (10 mg/kg). The median PFS was 11 months, with a 6-month PFS rate of 66.7%. The only FUS-related adverse event was transient scalp heating (grade 1; 1.9%). A fluid-attenuated inversion recovery normalization effect emerged within 1 month after treatment. Plasma cfDNA increased significantly post-FUS, with total cfDNA rising 2.03 ± 0.76-fold, EGFR cfDNA 1.77 ± 0.76-fold, and HMBS cfDNA 1.68 ± 0.66-fold. CONCLUSION: Repeated FUS-BEV treatment is safe and feasible in patients with recurrent glioblastoma. Randomized controlled trials are warranted to confirm its therapeutic efficacy and validate imaging and liquid biopsy biomarkers.